Completed
Fluconazole Treatment for Serious Mycoses in Patients Unresponsive to Conventional Therapy
What is being tested
Fluconazole
Drug
Who is being recruted
Blood-Borne Infections+14
+ Urogenital Diseases
+ Genital Diseases
Over 18 Years
+6 Eligibility Criteria
How is the trial designed
Treatment Study
Interventional
Summary
Principal SponsorPfizer
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner
This study focuses on the use of a drug called Fluconazole for treating serious or life-threatening fungal infections. It's designed for patients who can't be treated with traditional antifungal therapies, either because those treatments didn't work or caused unacceptable side effects. The importance of this study lies in its potential to provide a solution for patients who are not eligible for other existing Fluconazole clinical trials, thereby addressing an unmet need in the treatment of serious fungal infections.
Principal SponsorPfizer
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Treatment Study
These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Conditions
Criteria
Any sex
Biological sex of participants that are eligible to enroll.Over 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Blood-Borne InfectionsUrogenital DiseasesGenital DiseasesBacterial Infections and MycosesCommunicable DiseasesImmunologic Deficiency SyndromesImmune System DiseasesInfectionsRetroviridae InfectionsRNA Virus InfectionsSexually Transmitted DiseasesVirus DiseasesSexually Transmitted Diseases, ViralLentivirus InfectionsCandidiasisMycosesHIV Infections
Criteria
4 inclusion criteria required to participate
Failure of conventional therapy to control or eradicate infection after appropriate trial(s) of generally accepted regimen(s)
OR A major contraindication to the use of conventional antifungal therapy
Patients with clinically established serious or life-threatening systemic fungal disease will be considered if conventional fungal therapy is not an acceptable alternative. Unacceptability of conventional therapy is defined as
Serious and unacceptable untoward reaction(s) to conventional antifungal therapy
2 exclusion criteria prevent from participating
A patient will be excluded if he/she has previously had an unacceptable adverse effect due to fluconazole
The patient must be ineligible or have no access to other established fluconazole investigational protocols. The final judgment of patient acceptability for inclusion lies with the Pfizer Clinical Monitor
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
CompletedOne Study Center